Nano-Cap Artelo Biosciences Stock Explodes — Glaucoma Study Collaboration Ignites Rally

ART27.13 is a peripherally selective synthetic cannabinoid.Glaucoma Study Collaboration Advances ART27.13 DevelopmentArtelo has entered into a Definitive Investigator-Initiated Study Agreement with the Belfast Health and Social Care Trust to explore ART27.13’s effects on intraocular pressure in patients with glaucoma.The study, funded by Glaucoma UK and the HSC R&D Division, is set to enroll its first patient in the second quarter of 2026, marking a pivotal step in expanding ART27.13’s clinical potential.Th ...